4CPS-034 Effectiveness and safety of monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (pcsk9 inhibitors) for the treatment of hypercholesterolaemia

BACKGROUND: Alirocumab and evolocumab (PCSK9-Inhibitors), are new drugs incorporated into the therapeutic arsenal for the treatment of hypercholesterolaemia, having shown effectiveness and safety in the performed clinical trials. PURPOSE: To assess the effectiveness and safety of PCSK9-Inhibitors, t...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Hosp Pharm
Autori principali: Ambel, H Quiros, Rengifo, C Donoso, Sacristán, AA García, Sesmero, JM Martinez, Barahona, A Dominguez, Suarez, S González, Gomez, P Moya, Romero, C Blazquez
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Group 2018
Soggetti:
Section 4: Clinical pharmacy services
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535333/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.125
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi